Percutaneous coronary intervention (PCI) is a common invasive cardiac procedure used to treat acute coronarysyndrome (ACS). The main objective of anticoagulant therapy in PCI is to minimize the risk of plaque rupture and decreasethe formation of blood clots. Understanding clinicians' prescription patterns is crucial for optimizing treatment strategiesfor patients with ACS who have undergone PCI. Methods: It was a cross-sectional, questionnaire-based, noninterventionalstudy which included questionnaire responses from 136 cardiologists, regarding usage of antiplatelets in ACS management.Results: Ticagrelor and aspirin dual antiplatelet therapy (DAPT) is favored by 54% cardiologists in managing ACS patientswho have undergone PCI, regardless of the presence or absence of type 2 diabetes mellitus (T2DM). Further, 78% of theparticipants preferred long-term DAPT over short-term and medium-term alternatives. Forty percent respondents preferreda 1-month triple antithrombotic therapy (TAT) for PCI patients with atrial fibrillation. Additionally, the study emphasizedthe importance of considering factors like age, bleeding history, hemoglobin, and creatinine clearance in determining theoptimal antithrombotic strategy. Conclusion: This study contributes valuable insights into the real-world practices of healthcare practitioners, paving the way for more informed and personalized ACS management strategies in Indian patients.